Equities

Zeria Pharmaceutical Co Ltd

4559:TYO

Zeria Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,117.00
  • Today's Change-13.00 / -0.61%
  • Shares traded19.00k
  • 1 Year change-7.96%
  • Beta0.3751
Data delayed at least 20 minutes, as of Jul 17 2024 05:53 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.

  • Revenue in JPY (TTM)75.73bn
  • Net income in JPY7.73bn
  • Incorporated1955
  • Employees1.78k
  • Location
    Zeria Pharmaceutical Co Ltd10-11, Nihombashi Kobuna-choCHUO-KU 103-8351JapanJPN
  • Phone+81 336632351
  • Fax+81 336632352
  • Websitehttps://www.zeria.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cuorips Inc23.10m-632.18m62.15bn59.00--10.37--2,690.30-86.04-86.043.14752.260.00474.6617.57391,559.30-12.94---13.30--41.69---2,736.49--33.80--0.00---39.65---39.84------
Katakura Industries Co., Ltd.39.83bn3.01bn71.17bn1.04k22.230.868312.091.7990.9090.901,203.272,327.460.28582.354.4938,300,000.002.292.352.993.3438.3037.758.018.322.58--0.109718.8116.62-2.048.0918.87-7.4610.76
ASKA Pharmaceutical Holdings Co Ltd62.84bn7.55bn73.99bn762.009.091.117.251.18266.48266.482,219.582,186.080.70661.694.0882,471,130.008.484.6311.085.8748.8046.9412.016.761.49--0.132814.863.946.1278.0334.04-37.8923.36
JCR Pharmaceuticals Co Ltd42.87bn5.51bn82.35bn934.0014.461.419.431.9243.9243.92342.31450.130.43490.58913.2945,900,430.005.628.668.4713.4672.9074.5112.9218.241.2227.690.293230.6024.8313.1146.008.1918.5421.67
Torii Pharmaceutical Co Ltd56.28bn5.29bn109.87bn583.0020.290.900719.131.95188.05188.052,002.444,235.560.42882.722.2596,531,740.004.036.524.447.3544.8349.559.4017.985.58--0.0024.1711.74-2.674.4428.76-20.3820.11
Kyorin Pharmaceutical Co Ltd119.53bn5.32bn111.00bn2.04k18.640.759111.550.928692.7092.702,082.822,276.510.67591.342.6158,536,730.003.013.053.903.7943.0147.114.454.761.45--0.138967.745.531.0212.68-4.987.41-7.06
Zeria Pharmaceutical Co Ltd75.73bn7.73bn114.21bn1.78k12.261.197.491.51175.39175.391,717.901,806.330.53041.483.9942,614,000.005.393.898.396.2873.2971.9310.167.570.794611.750.373535.0910.744.1424.7817.4920.775.29
Mochida Pharmaceutical Co Ltd102.89bn4.55bn126.27bn1.52k26.680.933617.171.23126.33126.332,868.833,609.590.64781.863.2867,598,550.002.864.373.445.3150.6152.474.426.713.31--0.002945.16-0.3641-1.26-31.61-11.6310.91-1.21
Nxera Pharma Co Ltd16.43bn-9.07bn151.04bn350.00--2.28--9.19-107.30-107.30194.96736.600.1309--5.7746,954,280.00-7.23-0.6588-7.78-0.703674.4489.83-55.20-4.464.03-10.910.5238---18.00---1,982.98------
Towa Pharmaceutical Co Ltd227.93bn16.17bn157.38bn4.59k9.300.96464.620.6905328.58328.584,630.883,167.260.56841.513.7049,680,470.004.034.215.035.6335.7039.237.107.231.46--0.564921.019.1316.74634.803.7228.2010.86
Kissei Pharmaceutical Co Ltd75.58bn11.16bn160.51bn1.78k13.200.65410.332.12246.57246.571,669.954,977.430.31351.562.9442,483,980.004.683.615.053.9049.4149.4714.9412.694.43--0.007834.8711.980.89196.0015.286.5810.40
Sumitomo Pharma Co Ltd314.56bn-314.97bn163.93bn4.98k--1.05--0.5212-792.79-792.79791.76392.820.3081.214.0563,164,260.00-30.84-5.07-54.58-7.7359.7669.99-100.12-12.280.2992--0.7332---43.38-7.29-322.71--4.02--
Data as of Jul 17 2024. Currency figures normalised to Zeria Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

7.80%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 May 20241.25m2.35%
Nomura Asset Management Co., Ltd.as of 31 May 2024858.90k1.62%
Nikko Asset Management Co., Ltd.as of 05 Jul 2024407.10k0.77%
Daiwa Asset Management Co. Ltd.as of 31 May 2024384.10k0.72%
Norges Bank Investment Managementas of 31 Dec 2023345.30k0.65%
Dimensional Fund Advisors LPas of 04 Jul 2024254.60k0.48%
BlackRock Japan Co. Ltd.as of 04 Jul 2024176.90k0.33%
Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jul 2024167.10k0.32%
Mellon Investments Corp.as of 03 Jul 2024150.50k0.28%
BlackRock Fund Advisorsas of 03 Jul 2024150.40k0.28%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.